Overview of Cara

Quick Facts: Cara (Leflunomide)

Property	Description
Active ingredient	Leflunomide
Form	Oral Tablet (Film-coated)
Pharmacological class	Disease-Modifying Antirheumatic Drug (DMARD)
Action principle	Pyrimidine synthesis inhibitor
Origin	Synthetic Isoxazole Derivative

What is Cara and What Does it Contain?

Cara is a brand name for the synthetic active substance Leflunomide, which is primarily taken as an oral tablet. This medication is classified chemically as an Isoxazole derivative and is a prescription-only medicine for systemic use. It is distinguished by its nature as a prodrug, meaning it requires conversion in the body to its active form, teriflunomide, to exert its therapeutic effect. This metabolic activation is a unique feature of the substance.

Classification of Cara: A Disease-Modifying Antirheumatic Drug (DMARD)

Leflunomide is formally classified as a conventional synthetic Disease-Modifying Antirheumatic Drug (DMARD) and an Immunosuppressive agent. This classification reflects its use in the long-term management of chronic autoimmune diseases. Its designation as a DMARD is clinically recognized for its potential to alter the underlying disease course.

The core action of Leflunomide is centered on its function as a pyrimidine synthesis inhibitor. By blocking an essential enzyme (dihydroorotate dehydrogenase, DHODH), the medicine reduces the ability of activated T-lymphocytes to multiply, thereby controlling the overactive immune response responsible for inflammation.

What is the General Purpose of Taking Leflunomide?

The general therapeutic purpose of this Immunomodulatory agent is to achieve sustained control over autoimmune disease activity. The medication is typically used in the management of chronic inflammatory conditions, such as active Rheumatoid Arthritis and Psoriatic Arthritis. As a systemic treatment, its primary goal is to limit the progression of structural joint damage and help stabilize the patient’s condition over the long term, rather than only addressing acute symptoms.

Regulatory References

European Medicines Agency (EMA)

What side effects are possible with Cara?

Official Side Effects and Safety Characteristics

The safety profile of Cara (Leflunomide) is formally organized by regulatory authorities, classifying documented adverse reactions based on their expected frequency and the body system affected. All statements regarding safety, adverse events, and restrictions are derived exclusively from government prescribing information.

Classification	Examples of Documented Adverse Reactions (SOC)
Very Common (ge 1/10 patients)	Alopecia (increased hair loss), diarrhoea, nausea, headache, elevated liver enzyme levels (Hepatobiliary Disorders)
Common (ge 1/100 to <1/10 patients)	Vomiting, abdominal pain, rash, eczema, dizziness, mild increase in blood pressure (Vascular Disorders)
Rare (ge 1/10,000 to <1/1,000 patients)	Hepatitis, jaundice, severe liver damage (including fatal cases), eosinophilia
Very Rare (<1/10,000 patients)	Agranulocytosis, pancytopenia, severe anaphylactic reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis

Documented Serious Adverse Reactions

Regulatory labeling highlights specific serious and potentially life-threatening reactions. These include severe liver injury (including hepatic failure), interstitial lung disease (ILD), severe haematological reactions (such as pancytopenia), and severe cutaneous reactions. The drug's immunosuppressive properties may increase susceptibility to severe infections.

Population-Specific Safety Constraints

Official documents define use restrictions for certain patient groups. The medication is contraindicated in pregnant women due to the risk of fetal harm and in individuals with severe hepatic impairment, severe immunodeficiency states, or severe uncontrolled infections. Use is not recommended for patients under 18 years of age.

Exposure-Related Safety Patterns

It is noted in regulatory sources that common effects like the elevation of liver enzymes are typically observed more frequently at the start of treatment. Most cases of severe liver injury have been reported within the first six months of treatment.

The official safety information strictly documents a profile characterized by systemic risks that correspond to the medicine's classification as an immunosuppressive agent. The standard classification by frequency and organ system provides a standardized, hierarchical view of risks, from common events to highlighted, serious reactions.

Overdose and Emergency Response

Cara overdose information is strictly structured around documented clinical manifestations and regulator-mandated emergency procedures. Over-exposure may present with specific constitutional and gastrointestinal signs, including extreme tiredness, weakness, stomach pain, pale skin, and diarrhea. Official documents also note severe outcomes related to the liver, emphasizing the risk of severe liver injury or fatal liver failure. Acute signs documented in regulatory sources include a fast heartbeat and shortness of breath.

When to Seek Immediate Help

Life-threatening scenarios such as collapse, seizure, or trouble breathing are explicitly documented as requiring immediate contact with emergency services. Medical attention must also be sought immediately if signs of severe liver injury develop, such as yellowing of the skin or dark-colored urine.

Management and Monitoring

No specific antidote for a Cara overdose is known. Due to the very long half-life of the active substance, management focuses on the Accelerated Drug Elimination Procedure (washout). This procedure involves the administration of agents like Cholestyramine or Activated Charcoal to speed up drug clearance from the body. Regulatory guidance requires post-exposure monitoring of liver enzyme levels (ALT) weekly until the values have normalized. This elimination procedure is also mandated for confirmed exposure during pregnancy, reflecting a key population-specific consideration.

Therapeutic Uses of Cara

What Cara Treats: Main Uses and Benefits

Cara (Leflunomide) may be part of managing chronic autoimmune conditions. It is classified as a Disease-Modifying Antirheumatic Drug (DMARD), and plays a role in managing the underlying disease activity. The medication is considered relevant in conditions such as active Rheumatoid Arthritis (RA) and active Psoriatic Arthritis (PsA) for adult patients. The long-term therapeutic approach is commonly used to help with limiting the progression of structural joint changes, which supports the maintenance of joint integrity and assists with functional stability. This therapeutic benefit is considered relevant in patients whose condition exhibits moderate-to-severe activity.

This medication helps manage the common symptom clusters that interfere with daily life, including chronic joint pain, significant swelling (synovitis), and debilitating morning stiffness. Through its role in managing the systemic inflammation, Cara contributes to easing the overall symptom load and supports general well-being during symptomatic phases. It supports patients during episodes of heightened discomfort by assisting with functional stability. This supportive action helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Joint Symptoms
Primary Focus	Active Rheumatoid Arthritis and Active Psoriatic Arthritis.
Symptom Easing	Assists in relieving joint swelling, tenderness, and morning stiffness.
Core Benefit	Supports the maintenance of long-term functional stability.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Cara (Leflunomide) is officially indicated for adult patients (ge 18 years of age) for the treatment of active Rheumatoid Arthritis and active Psoriatic Arthritis. The regulatory status strictly defines which populations are excluded or require specific restrictions.

Eligibility Classification	Status and Specific Restrictions
Absolute Contraindication	Pregnancy, breastfeeding, and women of childbearing potential not using reliable contraception.
	Patients with severe hepatic impairment or acute/chronic liver disease.
	Patients with known hypersensitivity to leflunomide or its active metabolite.
	Patients with severe immunodeficiency states or severe hypoproteinaemia.
Use Not Recommended	Children and adolescents under 18 years of age (safety/efficacy not established).
	Patients with moderate to severe renal insufficiency.
Conditional Use/Caution	Patients with pre-existing impaired bone marrow function or those with uncontrolled hypertension.

Resulting Eligibility Structure The official labeling mandates that Cara must not be used by pregnant or breastfeeding women, or by individuals with severe liver damage, or specific immune/blood disorders. Use is confined to the adult population, as the medicine is formally not recommended for those under 18. These regulatory classifications are absolute and govern the population-based eligibility for this medicine.

What should I know about interactions with other medicines?

Cara Interactions with Other Medicines and Products

Cara (Lenacapavir) has a defined interaction profile established in official regulatory documents. Its interactions are primarily driven by its role as both a substrate of, and a modifier of, certain enzymes and transporters.

Interaction Classifications (High-Level)

Classification	Basis of Restriction (FDA/EMA)
Contraindicated	Coadministration with strong CYP3A inducers, such as Rifampin, Carbamazepine, Phenytoin, or the herbal product St. John’s Wort, due to the risk of significantly decreased Cara exposure.
Not Recommended	Coadministration with moderate CYP3A inducers (e.g., Efavirenz) or drugs that are combined strong inhibitors of CYP3A, P-gp, and UGT1A1.

Interacting Product Categories

Medicinal products are classified based on their effect on Cara's clearance pathways: the enzyme CYP3A and the transporters P-glycoprotein (P-gp) and UGT1A1. Strong inducers of these pathways are restricted to prevent the loss of therapeutic effect.

Interaction-Context Constraints

Cara is a moderate inhibitor of CYP3A. Due to its long half-life, this inhibitory effect may persist in the systemic circulation for up to nine months after the final subcutaneous dose. Consequently, drugs that are sensitive substrates of CYP3A may have increased exposure and potential for adverse effects if initiated during this nine-month period.

Timing-Based Interaction Rules

Administration of the oral loading dose of Cara must be separated by four hours from co-administered activated charcoal to prevent reduced absorption, as noted in the product labeling.

Mechanism of Action

Targeted Enzyme Inhibition and Pyrimidine Depletion

The mechanism of Cara begins with its conversion to the active metabolite, Teriflunomide, which acts as a reversible inhibitor of the mitochondrial enzyme Dihydroorotate Dehydrogenase (DHODH) . This enzyme is rate-limiting in the de novo pyrimidine synthesis pathway, an essential process for creating the nucleotide building blocks (like UMP) needed for DNA and RNA. By blocking DHODH, the drug depletes the internal pyrimidine supply, initiating a mechanism of action that is primarily cytostatic.

Selective Modulation of Activated T-Cells

The resulting nucleotide depletion disproportionately affects activated T-lymphocytes, which require a high rate of de novo synthesis to support their rapid proliferation and expansion, whereas resting cells can utilize alternative salvage pathways. This unique selectivity forces the rapidly dividing T-cells, which characterize heightened immune activity, into G1/S phase cell cycle arrest, suppressing their numbers and reducing the output of pro-inflammatory mediators. This cascade leads to the systemic physiological control of the chronic inflammatory cascade.

Mechanism-Determined Delay in Physiological Effect

The systemic physiological change is not immediate. The drug's action is constrained by the necessity for prodrug conversion and the time required for the active metabolite to accumulate and then functionally suppress the T-cell population dynamics. This requirement explains the delayed onset of the physiological effect, which becomes apparent over a period of weeks to months.

Dosage and Administration Information

How Cara is Used: Official Administration Guidelines

Cara, containing the active ingredient leflunomide, is a prescription medicine taken exclusively by the oral route as a film-coated tablet. Its administration follows a dual-phase dosing regimen for adult patients, with treatment initiation and subsequent management requiring supervision by specialists.

Standard Dosage Regimens

The standard approach involves initiating therapy with a Loading Dose of 100 mg once daily for three days to accelerate the active metabolite's concentration. This is followed immediately by the Maintenance Dose.

Indication	Typical Maintenance Dose	Maximum Daily Dose
Active Rheumatoid Arthritis (RA)	10 mg to 20 mg once daily	20 mg
Active Psoriatic Arthritis (PsA)	20 mg once daily	20 mg

If the 20 mg daily maintenance dose is not tolerated, the dose may be reduced to 10 mg once daily. The maximum recommended daily dosage is strictly 20 mg. The therapeutic effects usually become apparent after 4 to 6 weeks, and further improvement may continue for up to 4 to 6 months, consistent with long-term use as a DMARD.

Administration Context and Adjustments

The tablets should be swallowed whole with sufficient liquid and may be administered with or without food. If a dose is missed, standard practice is to skip the missed dose and continue the regular once-daily schedule.

For specific populations, no dosage adjustment is required for older adults (65 years and above) or for patients with mild renal insufficiency. However, use is not recommended in the pediatric population (patients below 18 years of age) or in patients with pre-existing hepatic impairment, or those with significant elevations of liver enzymes prior to treatment initiation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cara (Leflunomide)

Evidence for use in Active Rheumatoid Arthritis (RA)

Research exploring the medicine in active Rheumatoid Arthritis (RA) is supported by the body of evidence, primarily stemming from Randomized Controlled Trials (RCTs). These short- to intermediate-term studies were conducted during periods of increased symptom activity and often compared the medicine against an inactive substance (placebo) or against other existing Disease-Modifying Antirheumatic Drugs (DMARDs). The research primarily examined adult patients diagnosed with active, moderate-to-severe RA.

Studies monitored a range of outcomes related to systemic or functional imbalance, including established composite scores that track how the disease evolves in observed populations. These scores measure changes in joint counts for swelling and tenderness, overall disease activity, and patient-reported outcomes describing perceived discomfort. Studies observed that the proportion of patients meeting composite clinical response criteria varied across the study groups. Research describes patterns related to changes in these functional measures.

Structural Joint Damage Evidence

A critical focus of the research was studied for the medicine's association with outcomes related to structural joint damage. Long-term studies monitored structural outcomes by measuring changes in X-ray images of the joints over periods of up to one year or more. Studies monitored radiographic progression, reporting differences in the accumulation of joint damage between the groups.

Evidence for use in Active Psoriatic Arthritis (PsA)

For adult patients with active Psoriatic Arthritis (PsA), the research available is less extensive than that for RA. The evidence primarily includes a multinational, randomized, placebo-controlled trial, supplemented by smaller studies and observational data. This research examined patients whose conditions characterized by fluctuating or episodic manifestations involved both joint and skin symptoms.

Studies monitored outcomes related to physical discomfort and skin manifestations. Specifically, trials tracked joint swelling and tenderness using established criteria like the Psoriatic Arthritis Response Criteria (PsARC), and they tracked the severity of psoriasis using the PASI score. Studies observed differences in the proportion of patients meeting the PsARC criteria across the study groups.

What is Still Uncertain About the Research for Cara

The evidence for long-term use is subject to the research limitation frame that follow-up durations were limited in initial trials and that observational data often suffers from patient selection and loss over time. The results apply only to the populations studied in trials, and data for certain groups, such as pediatric populations, are still emerging. Furthermore, comparative evidence is lacking for certain pairings against newer DMARDs. Studies help show what has been observed so far, but the evidence highlights what is known and what is still uncertain regarding outcomes in all subgroups of patients.

Key Studies & References

Effects of leflunomide and methotrexate in rheumatoid arthritis detected by digital X-ray radiogrammetry and computer-aided joint space analysis (Structural Damage)

Frequently Asked Questions (FAQ)

Common questions about Cara (FAQ)

Q: Can Cara cause changes in mood or behavior?

A: Official safety data indicates that the medicine may be associated with nervous system disorders, which commonly include effects like dizziness and paresthesia (a burning or tingling sensation). Changes in mood or behavior, such as anxiety, have also been reported in post-marketing or clinical experience. Any concerning changes should be brought to the attention of a healthcare professional.

Q: Why are people talking about the long-term safety of Cara?

A: Regulatory documents mention that follow-up periods in the initial clinical trials were limited in duration. However, the medicine has been studied in longer-term research to monitor structural outcomes and track its effects over extended use. Regulatory bodies emphasize the need for ongoing monitoring to track safety over the course of treatment.

Q: Is Cara safe to take with common over-the-counter pain relievers?

A: Official guidance recommends caution when the medicine is administered with other medications that are known to be potentially harmful to the liver, a category that can include some over-the-counter pain relievers. Official prescribing information includes warnings regarding potential liver injury. Due to this, monitoring of liver enzyme levels is often recommended when these combinations are used.

Q: Can Cara affect my ability to drive or operate machinery?

A: Dizziness is documented in official prescribing information as a common side effect of the medicine. The potential for dizziness or other effects that impair concentration means caution is generally recommended regarding activities that require full mental alertness, such as driving or operating machinery.

Q: Can taking Cara with alcohol cause dangerous interactions?

A: Yes, official warnings caution that the consumption of alcohol while taking this medicine may significantly increase the risk of severe liver damage. The official product information strongly advises against combining the medicine with heavy alcohol consumption to avoid increasing the risk of serious liver damage.

Q: Is it true that Cara can interact with grapefruit juice?

A: Official prescribing information addresses drug and herbal product interactions but does not identify grapefruit juice as a specific prohibited interaction. General food instructions state that the medicine may be taken with or without food.

Q: Are there specific vitamins or supplements that interact with Cara?

A: The official interaction profile specifies that the herbal product St. John’s Wort is prohibited because it can significantly reduce the amount of medicine available in the body. Patients in clinical trials were frequently administered a form of folic acid, a B vitamin, as a supplement. Consulting a healthcare professional is necessary regarding the use of specific supplements while taking this medicine.

Q: What is the process for discontinuing Cara use?

A: Due to the slow elimination of the active substance from the body, which results in effects persisting for an extended period, an accelerated drug elimination procedure (washout) is often recommended when discontinuing treatment. This procedure is typically recommended when switching to another medicine, planning pregnancy, or in cases of severe side effects. It usually involves administering substances like activated charcoal or cholestyramine.

Q: Is Cara known to cause weight gain or loss?

A: Weight loss is listed in official safety documents as a common side effect of the medicine, meaning it occurred in at least 1% but less than 10% of patients in clinical trials.

Q: Can Cara make certain skin conditions worse?

A: Official documents note that side effects include rash and eczema, and in very rare cases, severe skin reactions have been reported. While the medicine treats Psoriatic Arthritis, its effect on non-PsA skin conditions is not explicitly detailed in warnings. Information regarding specific, pre-existing skin conditions should be obtained from a healthcare professional.

Q: How quickly does Cara leave the body after stopping use?

A: The active substance has a prolonged half-life, a measure of how long it stays in the body, with concentrations persisting over an extended period. Regulatory information indicates that the half-life typically ranges from 1 to 4 weeks. For this reason, an accelerated drug elimination (washout) procedure is available to help reduce the amount in the blood more quickly.

Q: Can Cara cause problems with sleep?

A: Official regulatory documents list some nervous system disorders, but specific sleep problems like insomnia are not typically listed among the most frequent side effect categories. Any side effects that affect mood or behavior should be brought to the attention of a healthcare professional.

Q: Can men and women use Cara in the same way?

A: The dosage and general administration regimen are the same for all adult patients, regardless of sex. However, official information contraindicates the medicine for women who are pregnant or breastfeeding, and reliable contraception is necessary for women of childbearing potential due to the risk of fetal harm.

Q: Are there specific food interactions I should be aware of besides grapefruit?

A: The official labeling states that the medicine may be taken with or without food. Aside from the required separation of the medicine from activated charcoal (if used for elimination procedures), the official labeling does not specify any other general food interactions that must be avoided during daily use.

Q: Can I take other prescription medications while using Cara?

A: Yes, other prescription medications can be taken in general. However, official labeling specifies that certain categories of drugs are either prohibited (contraindicated) or not recommended due to serious interaction risks. These include strong enzyme inducers and certain medications that are also potentially harmful to the liver or blood cell counts.

Q: Is Cara used for pain management in some countries?

A: The documented purpose of the medicine is for the long-term treatment of active Rheumatoid Arthritis and Psoriatic Arthritis. It is classified as a disease-modifying antirheumatic drug (DMARD) intended to limit the progression of the underlying disease and structural joint damage, and its documented purpose is not pain management.

Q: What is the maximum duration for which Cara is usually prescribed?

A: The medicine is classified as a disease-modifying antirheumatic drug (DMARD) and is intended for the long-term management of chronic inflammatory conditions. Official prescribing information does not define an absolute maximum duration of use. The length of treatment is subject to determination by a healthcare professional based on the individual's condition.

How should Cara be stored and disposed of?

Storage Requirements

Cara (Leflunomide) tablets must be stored at a temperature not exceeding 25 C (77 F), with a common range of 15 C to 30 C. To maintain stability, the medication must be protected from light and moisture. Tablets should be kept in the original container or blister strip, which must be kept tightly closed and away from excess heat and freezing temperatures. A critical requirement is to keep this medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Cara tablets must not be thrown away with household waste or disposed of via wastewater, such as flushing down a sink or toilet. Proper disposal involves following local regulatory requirements or utilizing a national collection system designated for unused medicines.

Cara